William Blair Estimates Veracyte’s Q2 Earnings (NASDAQ:VCYT)

Veracyte, Inc. (NASDAQ:VCYT) – Stock analysts at William Blair upped their Q2 2025 earnings per share (EPS) estimates for Veracyte in a research note issued on Tuesday, May 13th. William Blair analyst A. Brackmann now anticipates that the biotechnology company will post earnings per share of $0.19 for the quarter, up from their prior forecast of $0.18. The consensus estimate for Veracyte’s current full-year earnings is $0.68 per share. William Blair also issued estimates for Veracyte’s Q3 2025 earnings at $0.19 EPS, Q4 2025 earnings at $0.25 EPS, FY2025 earnings at $0.80 EPS, Q1 2026 earnings at $0.13 EPS, Q2 2026 earnings at $0.21 EPS, Q3 2026 earnings at $0.23 EPS, Q4 2026 earnings at $0.31 EPS and FY2026 earnings at $0.88 EPS.

Veracyte (NASDAQ:VCYT) last released its quarterly earnings results on Monday, February 24th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.29 by $0.07. Veracyte had a positive return on equity of 3.02% and a negative net margin of 2.18%. The firm had revenue of $118.63 million for the quarter, compared to analyst estimates of $110.73 million. During the same quarter last year, the company posted ($0.39) earnings per share.

A number of other equities research analysts have also weighed in on the company. Stephens reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Veracyte in a report on Wednesday, March 26th. Guggenheim lowered their price objective on Veracyte from $45.00 to $37.00 and set a “buy” rating on the stock in a report on Wednesday, April 9th. Craig Hallum assumed coverage on Veracyte in a report on Thursday, March 20th. They issued a “buy” rating and a $45.00 price objective on the stock. StockNews.com lowered Veracyte from a “buy” rating to a “hold” rating in a report on Wednesday, February 26th. Finally, Needham & Company LLC decreased their price target on Veracyte from $51.00 to $41.00 and set a “buy” rating on the stock in a research note on Thursday, May 8th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $40.90.

Veracyte Trading Up 2.5%

Shares of VCYT opened at $29.20 on Friday. Veracyte has a twelve month low of $19.73 and a twelve month high of $47.32. The stock’s 50 day moving average is $30.83 and its two-hundred day moving average is $36.98. The firm has a market capitalization of $2.29 billion, a PE ratio of -194.67 and a beta of 2.14.

Institutional Trading of Veracyte

Institutional investors have recently made changes to their positions in the stock. Jones Financial Companies Lllp grew its stake in shares of Veracyte by 49.7% during the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 237 shares during the period. Versant Capital Management Inc grew its stake in shares of Veracyte by 1,267.6% during the 1st quarter. Versant Capital Management Inc now owns 930 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 862 shares during the period. Headlands Technologies LLC purchased a new stake in shares of Veracyte during the 1st quarter valued at $48,000. GF Fund Management CO. LTD. purchased a new stake in shares of Veracyte during the 4th quarter valued at $64,000. Finally, US Bancorp DE grew its stake in shares of Veracyte by 57.4% during the 4th quarter. US Bancorp DE now owns 1,774 shares of the biotechnology company’s stock valued at $70,000 after buying an additional 647 shares during the period.

Veracyte Company Profile

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.